West Announces First-Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
West Pharma (WST) Tops Q1 EPS by 9c, Revenues Beat; Raises FY19 EPS Guidance, Affirms FY19 Revenue Outlook
April 25, 2019 6:10 AM EDTWest Pharma (NYSE: WST) reported Q1 EPS of $0.74, $0.09 better than the analyst estimate of $0.65. Revenue for the quarter came in at $443.5 million versus the consensus estimate of $430.67 million.
Net sales of $443.5 million grew 7%, organic sales growth was 11%Reported-diluted EPS of $0.73 increased... More